Skip to main content

Argenx

Argenx SE is a global biopharmaceutical enterprise discovering and developing antibody-based therapies for severe autoimmune diseases and rare disorders. The company conducts business operations through a single pharmaceutical segment focused on immunology innovation. Its primary commercialized therapy is efgartigimod, marketed as Vyvgart, approved for treating generalized myasthenia gravis and related auto-immune conditions. Revenue is generated predominantly from commercial prescription sales of Vyvgart through specialty pharmacy networks and healthcare systems globally. The firm holds a market-leading global position in the commercial development of neonatal Fc receptor antagonist therapies. Argenx is headquartered in Breda, Netherlands, with primary operational hubs in Ghent, Belgium, and listings on Euronext Brussels and NASDAQ.

43 of the funds FundTelligence covers report a position in Argenx.

Legal name
Argenx SE
Sector
Health Care
Country
Netherlands
Funds holding it
43
Exposure themes
Autoimmune diseases, Treatment, Women's Health

Funds holding Argenx

Showing the 8 largest of 43 funds holding it.

Loading...